Regenerative Medicines Market - HARD COPY

Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer’s, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years.

Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies.
The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.
The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into ‘product’, ‘therapy’, ‘application’, and ‘geographical regions’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market.
This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same.
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges, and opportunities in the global regenerative medicine market?
• How did the regenerative medicine market evolve, and what is its scope in the future?
• What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2017 and 2025?
• How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2017-2025?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• What will be the growth rate of the tissue engineering segment during the forecast period?
• Which therapy segment is expected to register the highest CAGR for the regenerative medicine market?
• How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market?
• What will be the value of immune-oncology segment by 2025?
• Which geographical location will contribute to the highest sales of regenerative medicine?
The key players that have been contributing significantly to the regenerative medicine market are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics, among others.
Executive Summary
1 Report Scope
1.1 Scope of the Report
1.2 Global Regenerative Medicine Market Segmentation
1.3 Research Methodology
1.3.1. Data Triangulation
1.3.2. Key Data Points From Secondary Sources
1.3.3. Key Data Points From Primary Sources
1.3.4. Top-Down Approach (Segmental Analysis)
1.3.5. Bottom-Up Approach (Segmental Analysis)
1.3.6. Assumptions and Limitations
1.3.7. Data and Prediction Modelling
2 Market Overview
2.1. Introduction
2.2. Evolutionary History
2.3. Present And Future
3 Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
4 Competitive Landscape
4.1. Share of Key Developments & Strategies
4.2. Market Share Analysis
4.3. Porter's Five Force Analysis
5 Global Regenerative Medicines Market, by Therapy
5.1. Cell Therapy
5.2. Gene Therapy
5.3. Tissue Engineering
6 Global Regenerative Medicines Market, by Product (Qualitative)
6.1. Introduction
6.2. Acellular Products
6.3. Cellular Products
6.4. Products
6.5. Pipeline Products
7 Global Regenerative Medicines Market, by Application
7.1. Introduction
7.2. Orthopaedic & Dental
7.3. Cardiology
7.4. Wound Healing
7.5. Diabetes
7.6. Immuno-Oncology
7.7. Others
8 Global Regenerative Medicines Market, by Region
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9 Company Profiles
9.1. Acelity
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Financials
9.1.3.1. Financial Summary
9.1.4. Acelity: SWOT Analysis
9.2. Athersys, Inc.
9.2.1. Overview
9.2.2. Product Pipeline
9.2.3. Financials
9.2.3.1. Financial Summary
9.2.4. Athersys, Inc.: SWOT Analysis
9.3. Cellular Biomedicine Group, Inc.
9.3.1. Overview
9.3.2. Product Pipeline
9.3.3. Financials
9.3.4. Cellular Biomedicine Group, Inc.: SWOT Analysis
9.4. Cytori Therapeutics
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Financials
9.4.3.1 Financial Summary
9.4.4. Cytori Therapeutics: SWOT Analysis
9.5. Integra Lifesciences Corporation
9.5.1. Overview
9.5.2 Product Portfolio
9.5.3. Financials
9.5.3.1. Financial Summary
9.5.4. Integra Lifesciences Corporation: SWOT Analysis
9.6. Mesoblast Limited
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. Mesoblast Limited: SWOT Analysis
9.7. MiMedx Group Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. MiMedx Group Inc.: SWOT Analysis
9.8. Novartis International AG
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Financials
9.8.3.1 Financial Summary
9.8.4. Novartis International AG: SWOT Analysis
9.9. NuVasive, Inc.
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Financials
9.9.3.1 Financial Summary
9.9.4. Nuvasive, Inc: SWOT Analysis
9.10. Organogenesis Inc.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Corporate Summary
9.10.4. Organogenesis Inc.: SWOT Analysis
9.11. OSIRIS THERAPEUTICS, INC.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
9.12. STRYKER CORPORATION
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Financials
9.12.3.1. Financial Summary
9.12.4. STRYKER CORPORATION: SWOT Analysis
9.13. TERUMO CORPORATION
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Financials
9.13.3.1 Financial Summary
9.13.4. TERUMO CORPORATION: SWOT Analysis
9.14. TiGenix
9.14.1. Overview
9.14.2. Product Pipeline
9.14.3. Financials
9.14.3.1 Financial Summary
9.14.4. TiGenix: SWOT Analysis
9.15. Tissue Regenix
9.15.1. Overview
9.15.2. Product Portfolio & Product Pipeline
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. Tissue Regenix: SWOT Analysis
9.16. Vericel Corporation
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Financials
9.16.3.1. Financial Summary
9.16.4. Vericel Corporation: SWOT Analysis
9.17. ViaCyte, Inc.
9.17.1. Overview
9.17.2. Product Pipeline
9.17.3. Corporate Summary
9.17.4. ViaCyte, Inc.: SWOT Analysis
9.18. Zimmer Biomet Holdings Inc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Financials
9.18.3.1 Financial Summary
9.18.4. Zimmer Biomet Holdings Inc: SWOT Analysis
9.19. Anika Therapeutics
9.20. Capricor Therapeutics
9.21. COOK BIOTECH, INC.
9.22. Gamida Cell
9.23. Juno Therapeutics
List of Tables
1 Global Regenerative Medicines Market (2016 & 2025)
2 Comparison of Regenerative Medicines Market: China vs U.S.
3 Key Regional Markets for Regenerative Medicines
4 Percentage of Total Regional Population Aged 65 Years & Above: 2015 & 2030
5 Market Share Analysis, 2015-2017
6 Factors Affecting the Bargaining Power of Suppliers
7 Factors Affecting the Bargaining Power of Buyers
8 Factors Affecting Threat of New Entrants
9 Factors Affecting the Threat of Substitutes
10 Factors Affecting the Intensity of Competitive Rivalry
11 Global Stem Cells Market, by Country, 2016-2025 ($Million)
12 Global Gene Therapy Market, by Country, 2016-2025 ($Million)
13 Global Tissue Engineering Market, by Product Type, 2016-2025 ($Million)
14 Global Tissue Engineering Market, by Country, 2016-2025 ($Million)
15 Some of the Approved Regenerative Medicine Products
16 Products In The Pipeline
17 Overview: Acelity
18 Overview: Athersys, Inc.
19 Overview: Cellular Biomedicine Group, Inc.
20 Product Pipeline: Cellular Biomedicine Group, Inc.
21 Overview: Cytori Therapeutics
22 Overview: Integra LifeSciences Corporation
23 Overview: Mesoblast
24 Product Portfolio: Mesoblast
25 Overview: MiMedx Group Inc.
26 Overview: Novartis International AG
27 Overview: NuVasive, Inc.
28 Overview: Organogenesis Inc.
29 Overview: OSIRIS THERAPEUTICS, INC.
30 Overview: Stryker Corporation
31 Overview: Terumo Corporation
32 Overview: TiGenix
33 Product Pipeline: TiGenix
34 Overview: Tissue Regenix
35 Overview: Vericel Corporation
36 Overview: ViaCyte, Inc.
37 Product Pipeline: ViaCyte, Inc.
38 Overview: Zimmer Biomet Holdings Inc.
39 Overview: Anika Therapeutics, Inc.
40 Overview: Capricor Therapeutics
41 Overview: COOK BIOTECH, INC.
42 Overview: Gamida Cell
43 Overview: Juno Therapeutics
List of Figures
1 Regenerative Medicines Industry Sectors
2 Regenerative Medicines in Healthcare system
3 The Global Regenerative Medicines Market ($Billion)
4 Key Opportunities
5 Impact Analysis
6 Chronic Conditions: Key Statistics: 2016
7 Global Regenerative Medicines Market, by Therapy Type ($Million)
8 Global Regenerative Medicines Market, by Therapy, 2016
9 Global Regenerative Medicines Market, by Therapy, 2025
10 Evolution of Tissue Engineered Products
11 Tissue Engineered Therapy Market, by Product Type ($Billion)
12 Global Regenerative Medicines Market, by Application, 2016
13 Global Regenerative Medicines Market, by Application, 2025
14 Global Regenerative Medicines Market Value, by Region, 2016 & 2025 ($Billion)
15 Global Regenerative Medicines Market, by Region, 2016
16 Global Regenerative Medicines Market, by Region, 2025
17 Competitive Landscape: Global Regenerative Medicines Market
18 Global Regenerative Medicines Market Share Analysis: 2016
19 Importance of sustainability criteria from a industry (Manufacturer) point of view
20 Global Regenerative Medicines Market Segmentation
21 Research Methodology
22 Data Triangulation
23 Key Data Points From Secondary Sources
24 Key Data Points From Primary Sources
25 Top-Down Approach (Segment wise Analysis)
26 Bottom-Up Approach (Segmental Analysis)
27 Assumptions and Limitations
28 Data and Prediction Modelling
29 Regenerative Medicine Types
30 Evolutionary History
31 The Present and Future of Regenerative Medicine
32 Market Dynamics
33 Share of Different Strategies in the Market
34 Porter’s Five Forces Analysis
35 Global Regenerative Medicines Market, By Therapy, 2016-2023 ($Million)
36 Some Of The Strategies Of Cell Therapy
37 Types of Cell Therapy
38 Types of Stem Cells
39 Global Stem Cell Market, 2016-2025 ($Billion)
40 Global Stem Cells Market, by Type, 2016-2025 ($Billion)
41 Cord Blood Banking Market, 2016-2025 ($Billion)
42 Stem Cells & Services Market, 2016-2025 ($Billion)
43 Global Stem Cell Therapies Market, 2016-2025 ($Billion)
44 Global Stem Cells Market, by region, 2016-2025 ($Million)
45 Types of Gene Therapy
46 Gene Therapy Techniques
47 Global Gene Therapy Market, 2016-2025 ($Million)
48 Global Gene Therapy Market, by Region, 2016-2025 ($Million)
49 Global Tissue Engineering Therapy Market, 2016-2025 ($Billion)
50 Global Bone, Tendon, Cartilage, Allograft, and Autografts Market, 2016-2025 ($Million)
51 Global Bone Graft Substitutes Market, 2016-2025 ($Million)
52 Global Bone Growth Factors and Spinal Stimulation Market, 2016-2025 ($Million)
53 Global Demineralised Bone Matrix Market, 2016-2025 ($Million)
54 Global Bone Morphogenetic Proteins Market, 2016-2025 ($Million)
55 Global Other Orthobiologics Market, 2016-2025 ($Million)
56 Global Platelet Rich Plasma Market, 2016-2025 ($Million)
57 Global Skin/Dermal Substitutes (Allo/Autografts) Market, 2016-2025 ($Million)
58 Global Bioengineered Skin/ Synthetic Substitutes Market, 2016-2025 ($Million)
59 Global Placenta/Amniotic Tissue Market, 2016-2025 ($Million)
60 Global Growth Factors Market, 2016-2025 ($Million)
61 Global Topical Biologics Market, 2016-2025 ($Million)
62 Global Tissue Heart Valves Market, 2016-2025 ($Million)
63 Global Vascular Synthetic Grafts and Patches Market, 2016-2025 ($Million)
64 Global Tissue Composits Market, 2016-2025 ($Million)
65 Global Others Market, 2016-2025 ($Million)
66 Types of Products
67 Global Regenerative Medicines Market, by Application
68 Global Regenerative Medicines Market, by Application, 2016-2025 ($Billion)
69 Types of Skin Regeneration
70 Types of Diabetes Mellitus
71 Regenerative Medicine In Oncology
72 Global Regenerative Medicines Market, by region
73 Global Regenerative Medicines Market, by region 2016-2025 ($Billion)
74 The U.S. Regenerative Medicines Market, 2016-2025 ($Million)
75 The U.S. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
76 Canada Regenerative Medicines Market, 2016-2025 ($Million)
77 Canada Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
78 Germany Regenerative Medicines Market, 2016-2025 ($Million)
79 Germany Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
80 France Regenerative Medicines Market, 2016-2025 ($Million)
81 France Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
82 Italy Regenerative Medicines Market, 2016-2025 ($Million)
83 Italy Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
84 The U.K. Regenerative Medicines Market, 2016-2025 ($Million)
85 The U.K. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
86 Spain Regenerative Medicines Market, 2016-2025 ($Million)
87 Spain Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
88 Netherlands Regenerative Medicines Market, 2016-2025 ($Million)
89 The Netherlands Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
90 Belgium Regenerative Medicines Market, 2016-2025 ($Million)
91 Belgium Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
92 Rest of Europe Regenerative Medicines Market, 2016-2025 ($Million)
93 Rest of Europe Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
94 Japan Regenerative Medicines Market, 2016-2025 ($Million)
95 Japan Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
96 China Regenerative Medicines Market, 2016-2025 ($Million)
97 China Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
98 South Korea Regenerative Medicines Market, 2016-2025 ($Million)
99 South Korea Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
100 Australia Regenerative Medicines Market, 2016-2025 ($Million)
101 Australia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
102 India Regenerative Medicines Market, 2016-2025 ($Million)
103 India Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
104 Malaysia Regenerative Medicines Market, 2016-2025 ($Million)
105 Malaysia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
106 Singapore Regenerative Medicines Market, 2016-2025 ($Million)
107 Singapore Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
108 Rest of Asia Regenerative Medicines Market, 2016-2025 ($Million)
109 Rest of Asia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
110 Brazil Regenerative Medicines Market, 2016-2025 ($Million)
111 Brazil Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
112 Mexico Regenerative Medicines Market, 2016-2025 ($Million)
113 Mexico Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
114 Rest of LATAM Regenerative Medicines Market, 2016-2025 ($Million)
115 Rest of LATAM Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
116 KSA Regenerative Medicines Market, 2016-2025 ($Million)
117 KSA Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
118 Russia Regenerative Medicines Market, 2016-2025 ($Million)
119 Russia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
120 Israel Regenerative Medicines Market, 2016-2025 ($Million)
121 Israel Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
122 The UAE Regenerative Medicines Market, 2016-2025 ($Million)
123 The UAE Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
124 Rest of World Regenerative Medicines Market, 2016-2025 ($Million)
125 Rest of World Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
126 Acelity: Product Portfolio
127 Acelity: SWOT Analysis
128 Athersys, Inc.: Product Pipeline
129 Athersys, Inc.: SWOT Analysis
130 Cellular Biomedicine Group, Inc.: SWOT Analysis
131 Cytori Therapeutics: Product Portfolio
132 Cytori Therapeutics: SWOT Analysis
133 Integra LifeSciences Corporation: Product Portfolio
134 Integra LifeSciences Corporation: SWOT Analysis
135 Mesoblast Limited: SWOT Analysis
136 MiMedx Group Inc.: Product Portfolio
137 MiMedx Group Inc.: SWOT Analysis
138 Novartis International AG: Product Portfolio
139 NuVasive, Inc.: Product Portfolio
140 NuVasive, Inc.: SWOT Analysis
141 Organogenesis Inc: Product Portfolio
142 Organogenesis Inc: SWOT Analysis
143 OSIRIS THERAPEUTICS, INC.: Product Portfolio
144 OSIRIS THERAPEUTICS, INC.: SWOT Analysis
145 STRYKER CORPORATION: Product Portfolio
146 STRYKER CORPORATION: SWOT Analysis
147 TERUMO CORPORATION: Product Portfolio
148 TERUMO CORPORATION: SWOT Analysis
149 TiGenix: Product Portfolio
150 TiGenix: SWOT Analysis
151 Tissue Regenix: Product Portfolio
152 Tissue Regenix Group plc: SWOT Analysis
153 Vericel Corporation: Product Portfolio
154 Vericel Corporation: SWOT Analysis
155 Zimmer Biomet Holdings Inc: Product Portfolio
156 Zimmer Biomet Holdings Inc: SWOT Analysis
The increased prevalence of chronic and genetic diseases has led to the high demand for better medicines. The existing therapies mostly treat the symptoms of the disease. But there was an impending need to identify the root-causes of any disease and then treat it accordingly. This need was effectively met with the advent of regenerative medicines in the medical world. Regenerative medicine is defined as the therapy involving the replacement or repair of the damaged tissue or organs, thereby completely curing the disease. The discovery of stem cells, the development of laboratory culture techniques, and the characterisation of pluripotent, and different stem cell types have together led to the development of regenerative medicine.
Regenerative medicine represents a new paradigm in human health, with the potential to resolve unmet medical needs by addressing the underlying causes of disease. Regenerative medicine research translates fundamental knowledge in biology, chemistry and physics into materials, devices, systems and a variety of therapeutic strategies which augment, repair, replace or regenerate organs and tissues. This rapidly evolving, interdisciplinary field in healthcare is transforming the practice of medicine, medical innovation and the production of medical devices and therapies.
The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region. The global regenerative medicines market is expected to reach $50.55 billion by 2025. The rapid expansion of the stem cell and gene therapy in the developed markets such as the U.S., Japan, Germany, and the U.K. is key driver for growth of regenerative medicines market.
As the world population is aging at a much faster pace, and the prevalence of diseases is rising, the demand is increasing for regenerative medicines that not only cure the chronic conditions completely but also improve the quality of life of the patients. Other factors contributing to the growth of the regenerative medicine market include the rising awareness about regenerative medicine, technological advancements, and better efficacy, and safety provided by such products. The major challenge to the growth of the market constitutes the changing regulatory environment. The stringent regulations implemented by the concerned regulatory bodies for the regenerative medicine products is a challenging factor for the industry players.
The regenerative medicines market, cumulative of tissue engineering products, gene therapy, and stem cell therapy is fragmented in nature due to the involvement of numerous global as well as regional players (700+) in this industry. Most of the companies in this sector are in clinical stage and are expected to launch their products in the coming few years.
The global regenerative medicines market is generally dominated by the global orthopedic and wound biologics companies, however, depending on the geographical areas the market of these players varies accordingly. Efficient distribution networks, product differentiation and supply competency play a major role in determining the market position of such players. Majority of these players are focusing on expanding distribution network as well as expanding presence, as Asia Pacific, Latin America and the Middle East are the developing regions and there is an increasing awareness about tissue and cell based products.
The global regenerative medicine market on the basis of therapy can be segmented into cell therapy, gene therapy, and tissue engineering. The major contributor towards the market in 2016 was tissue engineering market with an estimated value of $10.78 billion in 2016. Based on the application type, the market is segmented into orthopaedic, cardiovascular, wound healing, diabetes, immune-oncology, and others. Moreover, based on the product type, the market can be segmented into cellular, and acellular products. Geographically, the largest contributor to the growth of the global regenerative medicine market was North America, attributing to the presence of various biopharmaceutical companies involved in R&D of regenerative products in the region followed by Europe. The highest CAGR was observed for Asia-pacific region due to encouraging regulatory decisions for regenerative medicine such as in Japan.
Regenerative medicine cures the disease at the root cause, thus offering permanent treatment, unlike the palliative treatment offered by pharmaceutical products. The possibility of the development of a therapy for the treatment of rare, and orphan diseases, use of nanomaterials, and the recent development of cell free therapy, stem cell exosomes, present opportunities for the further growth of the global regenerative medicine market.
The report provides in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each. Some of the key players are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics.
North America
Europe
Asia Pacific
Rest of the World
Global Regenerative Medicines Market, regenerative medicine market, regenerative medicine market report, regenerative medicine market trends, growth of regenerative medicine, regenerative medicine market size, regenerative medicine market growth, regenerative medicine industry report, regenerative medicine market, Global Stem Cells Market, stem cell therapy market, Global Gene Therapy Market, Global Tissue Engineering Market
Due to the fall in the birth rates and increased life expectancy, the world population is aging rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer’s, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis would grow to 21% by 2040 from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In recent years, the prevalence of chronic diseases has been increasing irrespective of age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases and cancer has also witnessed a upsurge in the recent years.
Regenerative medicine presents with opportunities to change the treatment options and offers a complete cure for the diseases. The possibility of the development of therapy for the treatment of rare, and orphan diseases, use of nanomaterials, and the recent development of cell-free therapy, stem cell exosomes, present opportunities for the further growth of the regenerative medicine market.
According to a new market intelligence report by BIS Research, titled "Global Regenerative Medicine Market- Analysis and Forecast, 2017-2025", the global regenerative medicine market was estimated at $17.03 billion in 2016, and is estimated to grow over $50.55 billion by 2025. This robust growth can mainly be attributed to the escalating prevalence of chronic conditions, increasing geriatric population, and improved safety and outcomes provided by the regenerative medicine products.
According to Abdul Wahid, analyst at BIS Research, "The rising demand and popularity of stem cell, and gene therapies is because these new treatments offer a potential cure for the chronic diseases, unlike the lifelong treatment with pharmaceuticals. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies. Also, several agreements, partnerships, and collaborations can also be seen, indicating the interest of investors, and biopharmaceutical companies in regenerative medicine. Recently, Gilead Sciences announced the acquisition of Kite Pharma, a leading player in cell therapy, for $11.9 billion."
Research Highlights:
• Tissue engineered product segment (including biological and synthetic tissues/cells) currently dominates the market at 63% and generated $10.7 billion revenue. Gene therapy was the most lucrative and fastest growing segment is expected to grow at 31% through the forecast period.
• Orthopaedic and dental was the dominant application segment in 2016. The rising geriatric population, increased prevalence of musculoskeletal diseases, and higher incidence of bone and joint disorders are the main reasons for this trend. The fastest growing segment is expected to be immunology and oncology with a CAGR of 16.9% from 2017 to 2025.
• North America held the major share (39%) of the global regenerative medicines market in terms of revenue in 2016, followed by Europe with a share of 27%. This is mainly due to the presence of the leading players in the region along with higher advances in the stem and gene therapy technology.
• The fastest growing segment is expected to be the stem cell therapies segment, registering a CAGR of 22.1% during the forecast period 2017-2025. The stem cells therapies segment was valued at $1.20 billion in 2016, and is expected to reach $7.46 billion in 2025. Stem cell therapies are increasingly being adopted by the patients due to the benefits provided by them.
• Market share analysis of top 60 companies in this market have been done to understand the global market scenario
Source: BIS Research Analysis
This market intelligence report provides a multidimensional view of the global regenerative medicine market in terms of market size and growth potential. This research report aims at answering various aspects of the global regenerative medicine market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market and assesses the factors governing the same.
Key questions answered in the report:
• What are the major market drivers, challenges, and opportunities in the global regenerative medicine market?
• How did the regenerative medicine market evolve, and what is its scope in the future?
• What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2016, and 2025?
• How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2023?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016-2025?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• What will be the growth rate of the tissue engineering segment during the forecast period?
• Which therapy segment is expected to register the highest CAGR for the regenerative medicine market?
• How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market?
• What will be the value of immune-oncology segment by 2025?
• Which geographical location will contribute to the highest sales of regenerative medicine?
Acelity
Athersys, Inc.
Cellular Biomedicine Group, Inc.
Cytori Therapeutics
Integra Lifesciences Corporation
Mesoblast Limited
MiMedx Group Inc.
Novartis International AG
NuVasive, Inc.
OSIRIS THERAPEUTICS, INC.
STRYKER CORPORATION
TERUMO CORPORATION
TiGenix
Global Regenerative Medicine Market to Reach $50.55 Billion by 2025, Reports BIS Research